Due to the Russia-Ukraine war, Europe was witnessing surging electricity prices, making some electric vehicles more expensive than combustion engines. In some cases, the cost difference between driving both types…
Mersana Therapeutics Inc MRSN signed a deal for developing antibody-drug conjugates (ADCs) for cancer treatment with Germany’s Merck KGaA MKGAF MKKGY. Mersana would receive $30 million in an upfront payment and up to…
United Airlines Holdings Inc’s UAL Chicago-based pilot, Neil Swindells, elected to lead the United Airlines pilots’ union, has resigned after a series of his recent online posts sparked an outcry.…
Applied Molecular Transport Inc AMTI announced topline Phase 2 results from the LOMBARD monotherapy trial for AMT-101 in biologic-naïve and experienced patients with moderate-to-severe ulcerative colitis (UC). The clinical remission (CR)…
The FDA has approved Gilead Sciences Inc’s GILD Sunlenca (lenacapavir), in combination with another antiretroviral (s) (ARV), for HIV-1 infection in heavily treatment-experienced (HTE) adults with multi-drug resistant (MDR) HIV-1 infection. …
2022 was not a good year for investment banking, as a slump in deals led to declines in fees and revenues at all major institutions. Due to the…
Eli Lilly And Co LLY and ProQR Therapeutics N.V. PRQR have expanded their licensing and collaboration agreement focused on discovering, developing, and commercializing new genetic medicines. The collaboration, initially announced in September 2021,…
Britain’s Financial Reporting Council (FRC) imposed a penalty of £906,250 on Deloitte LLP over its audits of building materials supplier SIG plc for the 2015 and 2016 financial years. The penalty was…
HC Wainwright initiated coverage of PepGen Inc PEPG with a Buy rating and $26 price target. PepGen is developing next-generation antisense oligonucleotide (ASO) therapeutics for neuromuscular and neurologic diseases.…
Altimmune Inc ALT announced topline results from its 24-week (12-week extension) trial of pemvidutide in subjects with Non-Alcoholic Fatty Liver Disease (NAFLD). Sixty-six of the 83 subjects who completed the initial…
Satsuma Pharmaceuticals Inc STSA provided an update on its STS101 development program and corporate update. Further analysis of results from the recently-completed SUMMIT Phase 3 efficacy trial of STS101 for…
ContraFect Corporation CFRX has announced the database lock of its Phase 3 DISRUPT study of exebacase in patients with Staph aureus bacteremia, along with a summary of topline data from the interim futility…
The Paris Commercial Court slapped a fine of €1 million on Apple Inc AAPL for imposing abusive commercial clauses on French app developers for accessing its App Store. …
Galapagos NV GLPG is reportedly looking for M&A deals with companies with products still in the preclinical or early stage of development. The former chief scientific officer of Johnson &…
Applied UV Inc AUVI has agreed to acquire privately held PURO Lighting LLC and LED Supply Co that would effectively double the company’s size. Applied UV develops and acquires infection prevention and control technology in…
Assembly Biosciences Inc ASMB announced interim efficacy, safety, and pharmacokinetic (PK) results from a Phase 1b study of ABI-H3733 (3733) and a Phase 1a study of ABI-4334 (4334). For…
Bionomics Limited BNOX announced results from its Phase PREVAIL study of BNC210 for the acute treatment of Social Anxiety Disorder (SAD), showing a miss on the primary endpoint. HC Wainwright,…
Ardelyx Inc ARDX shares are down after an update regarding the appeal to the Complete Response Letter (received in July 2021) for the marketing application seeking approval for Xphozah (tenapanor). Peter…
The European Commission has approved AstraZeneca Plc AZN – Daiichi Sankyo’s DSKYF DSNKY Enhertu (trastuzumab deruxtecan) for advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. The approval covers patients who have received a…
AstraZeneca Plc AZN announced topline data from the PEARL Phase 3 trial of Imfinzi (durvalumab) monotherapy versus platinum-based chemotherapy (investigator’s choice) as a 1st-line treatment in patients with Stage IV (metastatic) non-small…